Endothelins (ET-1, ET-2 and ET-3) are 21-amino-acid peptides with two disulfide bonds that belong to the sarafotoxin family. ET-1, ET-2 and ET-3 are produced endogenously from preproendothelin to give big endothelins, which are cleaved by endothelin-converting enzyme (ECE) to yield the active protein. Endothelin has been shown to play important physiological and pathological roles by interacting with its G-protein-coupled receptors. There are two cloned ET receptors: the ET(A) receptor, which is selective for ET-1, and the ET(B) receptor, which binds ET-1, ET-2 and ET-3 with similar affinities. Since the discovery of endothelin, and especially since the availability of peptide ET antagonists such as BQ-123 and BQ-788, and nonpeptide compounds such as bosentan, considerable effort has been spent on better understanding the role of endothelin and its receptor antagonists. As a result, endothelin has been implicated in a variety of serious diseases, such as congestive heart failure, hypertension, pulmonary hypertension and prostate cancer. Research in pharmaceutical and biotechnology laboratories has generated many endothelin antagonists with either sulfonamide or triaryl carboxylic acid scaffolds, and a number of ET(A)-selective or nonselective ET(A)/ET(B) endothelin antagonists have entered clinical trials. This article will review the small-molecule ET(A)-selective and nonselective ET(A)/ET(B) antagonists that are under clinical evaluation, and highlight a member of this group of compounds, sitaxsentan. A summary of the medicinal chemistry that led to the identification of sitaxsentan will be presented, followed by selected animal and human clinical trial data. (c) 2001 Prous Science. All rights reserved.
Endothelin (ET) receptor antagonists, in particular ETA selective or ETA/ETB balanced antagonists, represent a new therapeutic area for serious diseases such as congestive heart failure (CHF) and pulmonary hypertension. Endothelin antagonists have profound effects on the pulmonary vasculature and the right heart whereas ACE inhibitors primarily affect the peripheral vessel and the left heart. Therefore, combination of endothelin antagonists and ACE inhibitors may be particularly useful in chronic heart failure. Pulmonary hypertension represents another unmet medical need where endothelin antagonists, especially orally-active compounds, show great promise. The importance of this field is evidenced by the number of compounds in clinical trials and by the number of patents filed in recent years. Between January 1997 and April 2000, there are 139 endothelin patents of which 128 are concerned with endothelin receptor antagonists and 11 with endothelin converting enzyme inhibitors. Of the 128 patents, 93 are ab...
The title compound was synthesized in 3 steps from readily available cyanoacetate and TFAA. The ester group allowed access to other functionalized isoxazole derivatives.